

Docket No. 203512US77

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: William M. CANFIELD

SERIAL NO: 10/023,889

GAU: 1645

FILED: December 21, 2001

EXAMINER:

FOR: METHOD OF PRODUCING HIGH MANNOSE GLYCOPROTEINS IN COMPLEX CARBOHYDRATE DEFICIENT CELLS



INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

COMMISSIONER FOR PATENTS  
ALEXANDRIA, VIRGINIA 22313

RECEIVED

AUG 01 2003

SIR:

Applicant(s) wish to disclose the following information.

TECH CENTER 1600/2901

REFERENCES

- ☒ The applicant(s) wish to make of record the references listed on the attached form PTO-1449. Copies of the listed references are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language references.
- ☒ A check is attached in the amount required under 37 CFR §1.17(p).

RELATED CASES

- ☐ Attached is a list of applicant's pending application(s) or issued patent(s) which may be related to the present application. A copy of the patent(s), together with a copy of the claims and drawings of the pending application(s) is attached along with PTO 1449.
- ☐ A check is attached in the amount required under 37 CFR §1.17(p).

CERTIFICATION

- ☐ Each item of information contained in this information disclosure statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

DEPOSIT ACCOUNT

- ☒ Please charge any additional fees for the papers being filed herewith and for which no check is enclosed herewith, or credit any overpayment to deposit account number 15-0030. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, MCCLELLAND,  
MAIER & NEUSTADT, P.C.

Richard L. Chinn, Ph.D.  
Registration No. 34,305



22850

Tel. (703) 413-3000  
Fax. (703) 413-2220  
(OSMMN 05/03)

Daniel J. Pereira, Ph.D.  
Registration No. 45,518



SHEET 1 OF 3

SERIAL NO.  
10/023,889

**RECEIVED**

AUG 01 2003

GROSS  
1645

TECH CENTER 1600/2900

Form PTO 1449  
(Modified)

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

ATTY DOCKET NO.  
203512US77

LIST OF REFERENCES CITED BY APPLICANT

APPLICANT  
William M. CANFIELD

FILING DATE  
December 21, 2001

**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						
	AM						
	AN						

**FOREIGN PATENT DOCUMENTS**

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES	NO
	AO	99/31117	06/24/99	WIPO		
	AP					
	AQ					
	AR					

**OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)**

AS	Ke-Wel ZHAO, et al., "Purification and characterization of human lymphoblast N-acetylglucosamine-1-phosphotransferase", Glycobiology, Vol. 2, no. 2, pp. 119-125, 1992	
AT	Takahiro NAGASE, et al., "Prediction of the Coding Sequences of Unidentified Human Genes. XV. The Complete Sequences of 100 New(cDNA Clones from Brain Which Code for Large Proteins <i>in vitro</i> ", DNA Research, Vol. 6, pp. 337-345, 1999	
AU	XP-002226186, "KIAA1206 protein (Fragment)", From Takahiro NAGASE, et al., "Prediction of the Coding Sequences of Unidentified Human Genes. XV. The Complete Sequences of 100 New(cDNA Clones from Brain Which Code for Large Proteins <i>in vitro</i> ", DNA Research, Vol. 6, pp. 337-345, 1999	
AV	XP-002226167, "Basic domain/leucine zipper transcription factor (Fragment), From CORDES, et al., "The mouse segmentation gene <i>kr</i> encodes a novel basic domain-leucine zipper transcription factor" (1994), Cell, Vol. 7, No. 9, pp. 1025-1034	<input type="checkbox"/> Additional References sheet(s) attached

Examiner

Date Considered

\*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



SHEET 2 OF 3

RECEIVED

AUG 01 2003

TECH CENTER 1600 2900

Form PTO 1449 (Modified)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY DOCKET NO. 203512US77		SERIAL NO. 10/023,889	
LIST OF REFERENCES CITED BY APPLICANT				APPLICANT William M. CANFIELD		GROUP 1645	
				FILING DATE December 21, 2001			
				U.S. PATENT DOCUMENTS			
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	BA						
	BB						
	BC						
	BD						
	BE						
	BF						
	BG						
	BH						
	BI						
	BJ						
	BK						
	BL						
	BM						
	BN						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES NO		
	BO						
	BP						
	BQ						
	BR						
	BS						
	BT						
	BU						
	BV						
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)							
	BW	Karen Gheesling MULLIS, et al., "Purification and Kinetic Parameters of Bovine Liver N-Acetylglucosamine-1-phosphodiester alpha-N-Acetylglucosaminidase", The Journal of Biological Chemistry, Vol. 269, No. 3, Issue of January 21, pp. 1718-1726, 1994					
	BX	Jin Kyu LEE, et al., "Purification and Characterization of Human Serum N-Acetylglucosamine-1-phosphodiester alpha-N-Acetylglucosaminidase", Archives of Biochemistry and Biophysics, Vol. 319, No. 2, June 1, pp. 413-425, 1995					
	BY	Theodore PAGE, et al., "Purification and characterization of human lymphoblast N-acetylglucosamine-1-phosphodiester alpha-N-acetylglucosaminidase", Glycobiology, Vol. 6, no. 6, pp. 619-626, 1996					
	BZ	Thomas J. BARANSKI, et al., "Lysosomal Enzyme Phosphorylation", The Journal of Biological Chemistry, Vol. 267, No. 32, Issue of November 15, pp. 23342-23348, 1992					
Examiner					<input type="checkbox"/> Additional References sheet(s) attached		
					Date Considered		
*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							



SHEET 3 OF 3

SERIAL NO.  
10/023,863**RECEIVED**

AUG 01 2003

GROUP

164

TECH CENTER 1600/2900

Form PTO 1449  
(Modified)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY DOCKET NO.  
203512US77

LIST OF REFERENCES CITED BY APPLICANT

APPLICANT  
William M. CANFIELDFILING DATE  
December 21, 2003

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	CA						
	CB						
	CC						
	CD						
	CE						
	CF						
	CG						
	CH						
	CI						
	CJ						
	CK						
	CL						
	CM						
	CN						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	CO					
	CP					
	CQ					
	CR					
	CS					
	CT					
	CU					
	CV					

## OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)

	CW	Ritva TIKKANEN, et al., "Several cooperating binding sites mediate the interaction of a lysosomal enzyme with phosphotransferase", The EMBO Journal, vol. 16, No. 22, pp. 6684-6693, 1997
	CX	Fumito MATSUURA, et al., "Human alpha-galactosidase A: characterization of the N-linked oligosaccharides on the intracellular and secreted glycoforms overexpressed by Chinese hamster ovary cells", Glycobiology, vol. 8, no. 4, pp. 329-339, 1998
	CY	Shiroh MAGUCHI, et al., "Elevated Activity and Increased Mannose-6-phosphate in the Carbohydrate Moiety of Cathepsin D from Human Hepatoma", Cancer Research, Vol. 48, pp. 362-367, January 15, 1988
	CZ	Norman W. Barton, et al., "Therapeutic response to intravenous infusions of glucocerebrosidase in a patient with Gaucher disease", Proc. Natl. Acad. Sci., USA, Vol. 87, pp. 1913-1916, March 1990
		<input type="checkbox"/> Additional References sheet(s) attached

Examiner

Date Considered

\*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



P.B. 5818 - Patentaan 2  
2280 HV Rijswijk (ZH)  
22 +31 70 240 2040  
TX 31651 epo nl  
FAX +31 70 240 3016

Europäisches  
Patentamt

European  
Patent Office


Office européen  
des brev ts

Zweigstelle  
in Den Haag  
Forschungs-  
abteilung

Branch at  
The Hague  
Search  
division

Département à  
La Haye  
Division de la  
recherche

Audier, Philippe André  
Brevalex,  
3, rue du Docteur Lancereaux  
75008 Paris  
FRANCE



Datum/Date

14. 04. 03

ichen/Ref./Réf.

SR 21180 US/EE

Anmeldung Nr./Application No./Demande n°. Patent Nr./Patent No./Brevet n°.

00961335.7

inhaber/Applicant/Demandeur/Patent/Inhaber/Proprietor/Titulaire

Canfield, William M.

## COMMUNICATION

The European Patent Office herewith transmits

- ☐ the European search report
- ☐ the declaration under Rule 45 EPC
- ☐ the partial European search report under Rule 45 EPC
- ☒ the supplementary European search report concerning the international application under Article 157(2) EPC relating to the above-mentioned European patent application. Copies of the documents cited in the search report are enclosed.

The following specifications given by the applicant have been approved by the Search Division :

- ☐ Abstract ☐ Title ☐ Figure
- ☐ The abstract was modified by the Search Division and the definitive text is attached to this communication.
- ☐ The following figure will be published with the abstract, since the Search Division considers that it better characterises the invention than the one indicated by the applicant.

Figure:

- ☒ Additional copy/copies of the documents cited in the European search report.

## REFUND OF THE SEARCH FEE

If applicable under Article 10 Rules relating to fees, a separate communication from the Receiving Section on the refund of the search fee will be sent later.



EPO Form 1507 02.93



### CLAIMS INCURRING FEES

The present European patent application comprised at the time of filing more than ten claims.

- ☐ Only part of the claims have been paid within the prescribed time limit. The present European search report has been drawn up for the first ten claims and for those claims for which claims fees have been paid, namely claim(s):
- ☐ No claims fees have been paid within the prescribed time limit. The present European search report has been drawn up for the first ten claims.

### LACK OF UNITY OF INVENTION

The Search Division considers that the present European patent application does not comply with the requirements of unity of invention and relates to several inventions or groups of inventions, namely:

see sheet B

- ☐ All further search fees have been paid within the fixed time limit. The present European search report has been drawn up for all claims.
- ☐ As all searchable claims could be searched without effort justifying an additional fee, the Search Division did not invite payment of any additional fee.
- ☒ Only part of the further search fees have been paid within the fixed time limit. The present European search report has been drawn up for those parts of the European patent application which relate to the inventions in respect of which search fees have been paid, namely claims:  
1-67, 74-105
- ☐ None of the further search fees have been paid within the fixed time limit. The present European search report has been drawn up for those parts of the European patent application which relate to the invention first mentioned in the claims, namely claims:



Although claims 74-81 are directed to a method of treatment of the human/animal body (Article 52(4) EPC), the search has been carried out and based on the alleged effects of the compound/composition.

Claim(s) searched incompletely:  
43, 49, 52, 57, 67, 69, 76, 79, 80

Reason for the limitation of the search:

Present claims 43, 52, 67, 69, 76, 79 and 80 and especially Claims 49 and 57 relate to an extremely large number of possible compounds or methods. Support within the meaning of Article 84 EPC and/or disclosure within the meaning of Article 83 EPC is to be found, however, for only a very small proportion of the compounds or methods claimed. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Unless the alternatives in said claims 43, 52, 67, 69, 76, 79 and 80 relate to a claim which itself is novel and inventive, they will give rise to further non-unity objections.

The same applies for claims 49 and 57 provided an attempt will be made to specify the compounds claimed.

In this context it should be emphasised that the drafting of the claims lies exclusively in the responsibility of the Applicant and that e.g. non-unity objections which arise due to the drafting of certain subject-matter in an independent form, cannot be cured by making reference to the fact that said independently claimed subject-matter forms part of a common (but unfortunately known) concept, e.g. two independently claimed steps of a known process.



The Search Division considers that the present European patent application does not comply with the requirements of unity of invention and relates to several inventions or groups of inventions, namely:

1. Claims: 1-18, 82, 84, 86, 88-105

GlcNAc-phosphotransferase and subunits thereof, an antibody binding it, nucleotide sequences encoding it or encoding the subunits, methods for producing the enzyme, vectors and host cell comprising the nucleotide sequences coding for the enzyme or the subunits

2. Claims: 19-34, 83, 85, 87

Phosphodiester alpha-GlcNAcase, an antibody binding it, nucleotide sequence encoding it, vectors and host cells comprising the nucleotide sequence and methods for producing the enzyme

3. Claims: 35-48

Method of modifying lysosomal hydrolases comprising contacting said lysosomal hydrolases with an isolated GlcNAc-phosphotransferase

4. Claims: 49-67

Phosphorylated lysosomal hydrolase comprising a mannose 6-phosphate amnd methods for preparing phosphorylated lysosomal hydrolase

5. Claims: 68-73

High mannose lysosomal hydrolase and methods for producing it

6. Claims: 74-81

Methods of treating a patient suffering from a lysosomal storage disease





European Patent  
Office

# SUPPLEMENTARY

## PARTIAL EUROPEAN SEARCH REPORT

Application Number

which under Rule 45 of the European Patent Convention shall be considered, for the purposes of subsequent proceedings, as the European search report

EP 00 96 1335

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
X	ZHAO K-W ET AL: "PURIFICATION AND CHARACTERIZATION OF HUMAN LYMPHOBLAST N ACETYLGLUCOSAMINE-1-PHOSPHOTRANSFERASE" GLYCOBIOLOGY, vol. 2, no. 2, 1992, pages 119-125, XP009003096 ISSN: 0959-6658 see the whole document	1,2	C12N9/12 C12N9/14 C12N1/20 C12N15/00 C07H21/04 A61K38/44 A61K38/51 C07K14/00
Y	---	35-48	
	---	---	
	---	---	
The supplementary search report has been based on the last set of claims valid and available at the start of the search.			TECHNICAL FIELDS SEARCHED (Int.Cl.7)
INCOMPLETE SEARCH			C12N
The Search Division considers that the present application, or some or all of its claims, does/does not comply with the EPC to such an extent that a meaningful search into the state of the art cannot be carried out, or can only be carried out partially, for the following claims:			
Claims searched completely:			
Claims searched incompletely:			
Claims not searched:			
Reason for the limitation of the search: see sheet C			
Place of search MUNICH		Date of completion of the search 26 March 2003	Examiner Grosskopf, R
CATEGORY OF CITED DOCUMENTS			
X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document			

6

EPF FORM 1555 03.92 (P44220)



European Patent  
Office

**SUPPLEMENTARY  
PARTIAL EUROPEAN SEARCH REPORT**

Application Number  
EP 00 96 1335

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
P,X	NAGASE T ET AL: "PREDICTION OF THE CODING SEQUENCES OF UNIDENTIFIED HUMAN GENES. XV. THE COMPLETE SEQUENCE OF 100 NEW CDNA CLONES FROM BRAIN WHICH CODE FOR LARGE PROTEINS IN VIVO" DNA RESEARCH, UNIVERSAL ACADEMY PRESS, JP, vol. 6, no. 5, October 1999 (1999-10), pages 337-345, XP000865804 ISSN: 1340-2838 see the whole document	8-10, 88-99	
P,X	-& DATABASE SWALLPROT 'Online! 1 May 2000 (2000-05-01) retrieved from EBI Database accession no. Q9ULL2 XP002226188 * abstract * 99.8% identity with SEQ ID NO: 1 from aa 308-930 and 100% identity with SEQ ID NO: 2 ---	8-10, 88-99	TECHNICAL FIELDS SEARCHED (Int.Cl.7)
X	DATABASE SWALLPROT 'Online! 1 November 1996 (1996-11-01) retrieved from EBI Database accession no. Q61340 XP002226187 57.9% identity with SEQ ID NO: 1 in 285 aa overlap (aa 645-930 of SEQ ID NO: 1) ---	8-10,91	
X	WO 99 31117 A (FLORENCE KIMBERLY ; HUMAN GENOME SCIENCES INC (US); FENG PING (US);) 24 June 1999 (1999-06-24) Human secreted protein encoded by gene 6 has 100% identity with SEQ ID NO: 3 see SEQ ID NO: 130 --- -/-	8-10, 102-105	



European Patent  
Office

**SUPPLEMENTARY**  
**PARTIAL EUROPEAN SEARCH REPORT**

Application Number

EP 00 96 1335

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
X	MULLIS KAREN GHEESLING ET AL: "Purification and kinetic parameters of bovine liver N-acetylglucosamine-1-phosphodiester alpha-N-acetylglucosaminidase." JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 269, no. 3, 1994, pages 1718-1726, XP002235767 ISSN: 0021-9258	19,20	
Y	see the whole document	21-34, 50-56	
X	LEE JIN KYU ET AL: "Purification and Characterization of Human Serum N-Acetylglucosamine-1-phosphodiester alpha-N-Acetylglucosaminidase." ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, vol. 319, no. 2, 1995, pages 413-425, XP002235768 ISSN: 0003-9861	19,20	TECHNICAL FIELDS SEARCHED (Int.Cl.7)
Y	see the whole document	21-34, 50-56	
X	PAGE THEODORE ET AL: "Purification and characterization of human lymphoblast N-acetylglucosamine-1-phosphodiester alpha-N-acetylglucosaminidase." GLYCOBIOLOGY, vol. 6, no. 6, 1996, pages 619-626, XP009008337 ISSN: 0959-6658	19,20	
Y	see abstract and page 624, right column, last par.	21-34	
	---		
	-/--		



European Patent  
Office

SUPPLEMENTARY  
PARTIAL EUROPEAN SEARCH REPORT

Application Number  
EP 00 96 1335

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (InCL17)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
Y	BARANSKI THOMAS J ET AL: "Lysosomal enzyme phosphorylation: I. Protein recognition determinants in both lobes of procathepsin D mediate its interaction with UDP-GlcNAc:Lysosomal enzyme N-acetylglucosamine-1-phosphotransferase." JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 267, no. 32, 1992, pages 23342-23348, XP002235769 ISSN: 0021-9258 see the whole document ---	35-48	
Y	TIKKANEN RITVA ET AL: "Several cooperating binding sites mediate the interaction of a lysosomal enzyme with phosphotransferase." EMBO (EUROPEAN MOLECULAR BIOLOGY ORGANIZATION) JOURNAL, vol. 16, no. 22, 17 November 1997 (1997-11-17), pages 6684-6693, XP002235770 ISSN: 0261-4189 see the whole document ---	35-48	TECHNICAL FIELDS SEARCHED (InCL17)
X	MATSUURA ET AL: "Human alpha-galactosidase A: characterization of the N-linked oligosaccharides on the intracellular and secreted glycoforms overexpressed by Chinese hamster ovary cells" GLYCOBIOLOGY, IRL PRESS., GB, vol. 8, no. 4, April 1998 (1998-04), pages 329-339, XP000925912 ISSN: 0959-6658 see abstract --- -/--	49, 57	




European Patent  
Office

**SUPPLEMENTARY**  
**PARTIAL EUROPEAN SEARCH REPORT**

Application Number  
EP 00 96 1335

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
X	MAGUCHI S ET AL: "ELEVATED ACTIVITY AND INCREASED MANNOSE 6-PHOSPHATE IN THE CARBOHYDRATE MOIETY OF CATHEPSIN D FROM HUMAN HEPATOMA" CANCER RESEARCH, vol. 48, no. 2, 1988, pages 362-367, XP009008325 ISSN: 0008-5472 see abstract	49,57	
X	BARTON N W ET AL: "THERAPEUTIC RESPONSE TO INTRAVENOUS INFUSIONS OF GLUCOCEREBROSIDASE IN A PATIENT WITH GAUCHER DISEASE" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 87, March 1990 (1990-03), pages 1913-1916, XP002905934 ISSN: 0027-8424 see the whole document	74-81	TECHNICAL FIELDS SEARCHED (Int.Cl.7)
X	BRADY R O ET AL: "Modifying Exogenous Glucocerebrosidase for Effective Replacement Therapy in Gaucher Disease." JOURNAL OF INHERITED METABOLIC DISEASE, vol. 17, no. 4, 1994, pages 510-519, XP009008428 ISSN: 0141-8955 see the whole document, esp. Fig. 4 ----- -/--	74-81	



**SUPPLEMENTARY**  
**PARTIAL EUROPEAN SEARCH REPORT**

Application Number

EP 00 96 1335

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
Y	KAKKIS E D ET AL: "OVEREXPRESSION OF THE HUMAN LYSOSOMAL ENZYME ALPHA-L-IDURONIDASE IN CHINESE HAMSTER OVARY CELLS" PROTEIN EXPRESSION AND PURIFICATION, ACADEMIC PRESS, US, vol. 5, no. 3, June 1994 (1994-06), pages 225-232, XP000857380 ISSN: 1046-5928 see the whole document	74-81	
Y	ZHAO KE-WEI ET AL: "Carbohydrate structures of recombinant human alpha-L-iduronidase secreted by Chinese hamster ovary cells." JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 272, no. 36, 1997, pages 22758-22765, XP002235771 ISSN: 0021-9258 see the whole document	74-81	TECHNICAL FIELDS SEARCHED (Int.Cl.7)
Y	ZIEGLER R J ET AL: "CORRECTION OF ENZYMATIC AND LYSOSOMAL STORAGE DEFECTS IN FABRY MICE BY ADENOVIRUS-MEDIATED GENE TRANSFER" HUMAN GENE THERAPY, XX, XX, vol. 10, no. 10, 1 July 1999 (1999-07-01), pages 1667-1682, XP001012918 ISSN: 1043-0342 see the whole document	74-81	
		-/-	



European Patent  
Office

**SUPPLEMENTARY  
PARTIAL EUROPEAN SEARCH REPORT**

Application Number  
EP 00 96 1335

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
Y	SUN HUAICHANG ET AL: "Retrovirus" vector-mediated correction and cross-correction of lysosomal alpha-mannosidase deficiency in human and feline fibroblasts." HUMAN GENE THERAPY, vol. 10, no. 8, 20 May 1999 (1999-05-20), pages 1311-1319, XP009008322 ISSN: 1043-0342 see the whole document	74-81	
Y	REUSER A J J ET AL: "Lysosomal storage diseases: Cellular pathology, clinical and genetic heterogeneity, therapy." ANNALES DE BIOLOGIE CLINIQUE, vol. 52, no. 10, 1994, pages 721-728, XP009008339 ISSN: 0003-3898 see pages 726-727 "Therapy"	74-81	TECHNICAL FIELDS SEARCHED (Int.Cl.7)

**ANNEX TO THE EUROPEAN SEARCH REPORT  
ON EUROPEAN PATENT APPLICATION NO.**

EP 00 96 1335

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

26-03-2003

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9931117      A	24-06-1999	AU 2306499 A	05-07-1999
		CA 2315295 A1	24-06-1999
		EP 1039801 A1	04-10-2000
		EP 1040117 A1	04-10-2000
		JP 2002508167 T	19-03-2002
		WO 9854963 A2	10-12-1998
		WO 9931117 A1	24-06-1999
		US 6525174 B1	25-02-2003
		AU 1931399 A	05-07-1999
		CA 2314379 A1	24-06-1999
		EP 1044210 A1	18-10-2000
		JP 2002508166 T	19-03-2002
		WO 9931116 A1	24-06-1999
		US 2001024813 A1	27-09-2001
		AU 6552198 A	29-09-1998
		EP 0973892 A2	26-01-2000
		JP 2001524814 T	04-12-2001
		WO 9840483 A2	17-09-1998
		US 6448230 B1	10-09-2002
		US 2002172994 A1	21-11-2002